Yosuke Sugiyama

10PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Nutrigenomics and personalised nutritionRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 02, 2026
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

|Jul 01, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

|Jan 13, 2026
Integrating pharmacokinetic modeling and wearable-derived physiological data to assess pain intensity in patients with advanced urologic cancer.

Yosuke Sugiyama, Yoshihiko Tasaki, Yoshihisa Mimura

|Jan 05, 2026
Establishment of a Patient-Derived Xenograft Model of a Testicular Yolk Sac Tumor.

Nobuhiko Shimizu, Taku Naiki, Aya Naiki-Ito

|Jun 27, 2024
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.

Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa

|May 11, 2024
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.

Toshiharu Morikawa, Taku Naiki, Yosuke Sugiyama

Pageof 2

Frequent Collaborators

10 joint publications

Taku Naiki

8 joint publications

Takahiro Yasui

6 joint publications

Toshiharu Morikawa

5 joint publications

Yoshihiko Tasaki